Previous studies, including DAPA-HF, EMPORER-Reduced, and DECLARE-TIMI 58, have focused on the efficacy of SGLT-2 inhibitors in reducing the risk of adverse cardiovascular events as the primary endpoint in patients with DM, HF, or AF. This evidence concerns the gene SLC5A2 and atrial fibrillation.